Xilio Therapeutics, Inc. — Director's Dealing 2021

Oct 22, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-10-21

Reporting Person: Giovine Salvatore (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$6.65	2031-03-28	Common Stock (233596)		Direct

Footnotes

F1: The option was granted on March 29, 2021 for 223,596 shares. On March 20, 2022, 25% of the underlying shares shall vest and the remaining shares shall vest in equal monthly installments until March 20, 2025.